Antimicrobial Activity of Plectasin NZ2114 in Combination with Cell Wall Targeting Antibiotics Against VanA-Type Enterococcus faecalis

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Elena B M BreidensteinDjalal Meziane-Cherif

Abstract

Antimicrobial peptide plectasin targeting bacterial cell wall precursor Lipid II has been reported to be active against benzylpenicillin-resistant Streptococcus pneumoniae but less potent against vancomycin-resistant enterococci than their susceptible counterparts. The aim of this work was to test plectasin NZ2114 in combination with cell wall targeting antibiotics on vancomycin-resistant Enterococcus faecalis. The activity of antibiotic combinations was evaluated against VanA-type vancomycin-resistant E. faecalis strain BM4110/pIP816-1 by disk agar-induction, double-disk assay, determination of fractional inhibitory concentration (FIC) index, and time-kill curve. The results indicated that plectasin NZ2114 was synergistic in combination with teicoplanin, moenomycin, and dalbavancin but not with vancomycin, telavancin, penicillin G, bacitracin, ramoplanin, daptomycin, and fosfomycin. To gain an insight into the synergism, we tested other cell wall antibiotic combinations. Interestingly, synergy was observed between teicoplanin or moenomycin and the majority of the antibiotics tested; however, vancomycin was only synergistic with penicillin G. Other cell wall active antibiotics such as ramoplanin, bacitracin, and fosfomycin did ...Continue Reading

References

Nov 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P E Reynolds
May 10, 1974·Annals of the New York Academy of Sciences·F M KahanH Kropp
Apr 1, 1997·The Journal of Antimicrobial Chemotherapy·G RavizzolaA Turano
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Predrag CudicDewey G McCafferty
Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·F C Odds
Feb 11, 2005·Chemical Reviews·Dan KahneChristopher Walsh
May 17, 2005·Combinatorial Chemistry & High Throughput Screening·D RaventósH-H Kristensen
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrice Courvalin
Mar 10, 2007·Science·Andrew L LoveringNatalie C J Strynadka
Oct 20, 2007·Biochimica Et Biophysica Acta·Walter R P ScottSuzana K Straus
Feb 12, 2008·Trends in Pharmacological Sciences·Françoise Van BambekePaul M Tulkens
Apr 30, 2008·Antimicrobial Agents and Chemotherapy·Kevin M KrauseBret M Benton
Oct 14, 2008·Expert Review of Anti-infective Therapy·Cesar A Arias, Barbara E Murray
Jan 7, 2009·Antimicrobial Agents and Chemotherapy·Douglas J BiedenbachRonald N Jones
May 29, 2010·Science·Tanja SchneiderHans-Henrik Kristensen
Jan 15, 2011·Trends in Biotechnology·Timothy D H BuggDavid I Roper
Mar 17, 2012·Nature Reviews. Microbiology·Cesar A Arias, Barbara E Murray
Jan 22, 2013·Trends in Biotechnology·Roberta J Worthington, Christian Melander
Aug 14, 2013·Proceedings of the National Academy of Sciences of the United States of America·Nicoleta J EconomouPatrick J Loll

❮ Previous
Next ❯

Citations

Jun 25, 2016·Applied Microbiology and Biotechnology·Tzi Bun NgWai Yee Chan
Jun 21, 2016·Materials·Diana Santos MoraisMaria Ascensão Lopes
May 25, 2021·Frontiers in Cellular and Infection Microbiology·Xuanxuan MaJianhua Wang
Mar 12, 2020·ACS Infectious Diseases·Declan Alan Gray, Michaela Wenzel

❮ Previous
Next ❯

Methods Mentioned

BETA
transglycosylation

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.